Cutaneous malignant melanoma: Scintigraphic detection of recurrent disease with Tc-99m MIBI

European Journal of Dermatology

Volumn 7, Issue 6, 1997, Pages 433-435

  Martinez, Miguel A ^a   Alonso, Omar ^a   Delgado, Lucía B ^a   Bazzano, Carlos I ^a   Garces, Mariela ^a   Lago, Graciela ^a   Priario, Julio ^a   Roca, Ricardo A ^a   Espasandin, Jose ^b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b Instituto Nacional de Oncologia Montevideo   (Uruguay)

Author keywords

Melanoma; Methoxyisobutylisonitrile (MIBI); Recurrent disease; Scintigraphy

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CANCER RISK; CASE REPORT; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEART PERFUSION; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; RECURRENT DISEASE; SCINTIGRAPHY; SKIN TUMOR;

EID: 0030931161     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Schlichter L, Serry D, Manangement of melanoma. In: Macdonald J., Haller D, Myer R, eds. Manual of oncologic therapeutics. Philadelphia: JB Lippincot Co, 1995; 252-8.
2. Jillella A, Mani S, Nair B, Poo WJ, et al. The role for close follow-up of melanoma patients with AJCC stages I-III: a preliminry analysis. Proc Am Soc Clin Oncol 1995; 14: 413 (abst.).
3. Morton D, Wong J, Kirkwood J, Parker L. Malignant Melanoma. In: Holland J, Frei E, Bast Jr R, Kufe D, Morton D, Weichselbaum R, eds. Cancer medicine. Malvern, Lea & Febinger, 1993; 1793-824.
4. Feggi L, Indelli M, Panisini GC, Santini A, et al. Immunoscintigraphy in mlignant melanoma: a five year clinical experience. Nucl Med Comm 1993; 14: 145-8.
5. Hoefnagel CA, Rankin EM, Valdes-Olmos R, Israels SP, et al. Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 1994; 21: 587-8.
6. Boni R, Boni RA, Steinert H, Burg G, et al. Staging of metastatic malignant melanoma by whole-body positron emmision tomography using 2-fluoride-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-62.
7. Alonso O, Martinez M, Logo G, Bazzano C, et al. Scintigraphy with Tc-99m MIBI in cutaneous melanoma. Clin Nucl Med 1996; 21: 557-9.
8. DePuey EG. An update on radiopharmaceuticals for myocardial perfusion imaging. J Nucl Med 1994; 35: 17N-21N.
9. Abdel-Dayem H, Scott AM, Macpinlac HA, El-Gazzar AH, et al. Role of 201-TI chloride and Tc-99m sestamibi in tumor imaging. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press, 1994; 181-234.
10. Zak IT, Seabold JE, Gurll NJ. Tc-99m MIBI scintigraphic detection of metastatic insular thyroid carcinoma. Clin Nucl Med 1995; 20: 31-6.
11. Alonso O, Lago G, Mut F, Hermida JC, et al. Thyroid imaging with Tc-99m MIBI in patients with cold single nodules on pertechnetate imaging. Clin Nucl Med 1996; 21: 363-7.
12. Piwnca-Worms D, Chiu ML, Kronuge JF. Uptake and retention of hexakis technetium (I) in cultured chick myocardical cells: mitochondrial and plasma membrane potential dependence. Circulation 1990; 77: 491-8.
13. Chen LB. Mithochondrial membrane potential in living cells. Annu Rev Biol 1988; 4: 155.
14. Rao V, Chiu ML, Kronauge JF. Expression of recombinant human multidrug resistance p-glycoprotein in insect cells confers decreased accumulation of technetium-99m sestamibi. J Nucl Med 1994; 35: 510-5.
15. Schadendorf D, Herfordt R, Czarenetzky BM. P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 1995; 132: 551-5.